Sincalide

Sincalide
Clinical data
Other names	1-De(5-oxo-L-proline)-2-de-L-glutamine-; 5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl); amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-; methylsulfanyl-butanoyl]amino]acetyl]amino]-3-; (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-; butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl); carbamoyl]propanoic acid
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Intravenous
ATC code	V04CC03 (WHO) ;
Legal status
Legal status	UK: Available on a named-patient basis; US: ℞-only;
Identifiers
	IUPAC name α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide;
CAS Number	25126-32-3 ;
PubChem CID	32800;
IUPHAR/BPS	864;
DrugBank	DB09142 ;
ChemSpider	8009168 ;
UNII	M03GIQ7Z6P;
KEGG	D05845 ;
ChEMBL	ChEMBL1121 ;
CompTox Dashboard (EPA)	DTXSID7048617 ;
ECHA InfoCard	100.042.384
Chemical and physical data
Formula	C49H62N10O16S3
Molar mass	1143.27 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N;
	InChI InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 ; Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N ;
	(what is this?) (verify)

Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.

Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

Clinical Use

Indications

Sincalide may be used to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals.^[1] It can also be used to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. In some instances it is used to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.^[2]

References

^ Ziessman HA (September 2019). "Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues". Journal of Nuclear Medicine Technology. 47 (3): 210–212. doi:10.2967/jnmt.119.226019. PMID 31019045. S2CID 131775567.
^ Kinevac Package Insert

External links

"KINEVAC (sincalide)]". DailyMed. U.S. National Library of Medicine.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Ziessman_2019-1] Ziessman HA (September 2019). "Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues". Journal of Nuclear Medicine Technology. 47 (3): 210–212. doi:10.2967/jnmt.119.226019. PMID 31019045. S2CID 131775567.

[2] Kinevac Package Insert

[1]

[2]